Related Experiment Video

Updated: Jun 19, 2026

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
10:11

Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue

Published on: January 3, 2013

23.1K

B7-H3 Inhibitors in Oncology Clinical Trials: A Review

Kavanya Feustel1, Jared Martin2, Gerald S Falchook1

  • 1Early Phase Clinical Trials Unit, Sarah Cannon Research Institute at HealthONE, Denver, CO, USA.

Journal of Immunotherapy and Precision Oncology
|February 8, 2024
PubMed

Insights

B7-H3 inhibitors show promise as cancer treatments. This review compiles clinical trial data on antibody-drug conjugates, radioimmunotherapy, and monoclonal antibodies targeting B7-H3 for various malignancies.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • B7-H3 is a transmembrane receptor frequently found on malignant cells.
  • Its precise role in adaptive immunity requires further elucidation.
  • B7-H3 is a promising target for novel cancer therapies.

Purpose of the Study:

  • To compile and review available clinical trial results for B7-H3 inhibitors in oncology.
  • To assess the efficacy of various B7-H3 targeting agents across different cancer types.

Main Methods:

  • Systematic review of published clinical trial data.
  • Analysis of preliminary efficacy and safety data for B7-H3 inhibitors.
  • Identification of ongoing and upcoming clinical trials.

Main Results:

  • B7-H3 inhibitors, including antibody-drug conjugates and monoclonal antibodies, demonstrate promising preliminary clinical efficacy.
  • Specific agents like enoblituzumab, 131I-omburtamab, and HS-20093 show potential in prostate, CNS, and lung cancers, respectively.
  • Emerging therapies such as CAR T-cell therapies targeting B7-H3 are under investigation.

Conclusions:

  • Targeted B7-H3 inhibition represents a new frontier in antineoplastic therapy.
  • Further clinical studies are essential to fully establish the efficacy and safety of B7-H3 inhibitors in both solid and hematologic malignancies.
Keywords:
B7-H3CD276cancerclinical trialreview

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.9K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...